Levate

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levate

What is Levate? Overview and Identity

Quick Facts Description
Active ingredient Amitriptyline Hydrochloride (Amitriptyline HCl)
Form Oral tablet (Film-coated)
Pharmacological class Tricyclic Antidepressant (TCA)
Common use Modulation of mood and psychological balance
Origin Synthetic chemical compound

What Type of Medicine is Levate and What is it Made Of?

Levate is a prescription medication whose active pharmacological ingredient is the synthetic compound Amitriptyline, specifically utilized as Amitriptyline Hydrochloride. It is classified as an Antidepressant belonging to the well-established Tricyclic Antidepressant (TCA) class. This classification reflects the drug's primary category and chemical nature, indicating its foundational role in central nervous system function.

The Amitriptyline compound is characterized as a tertiary amine with a distinct three-ring chemical structure. This compound is clinically recognized for its efficacy within the TCA group. The drug is supplied as a single-entity product, meaning that Amitriptyline is the only active substance present, and its synthetic origin means it is derived entirely from chemical processes.

Levate's Physical Form and General Function

Levate is supplied as an oral tablet, which is a solid, film-coated formulation designed for ingestion via the oral route of administration. Its general function is to provide psychological balancing and exert an overall antidepressant effect, a typical use being the stabilization of severely lowered mood states.

Its core mechanism involves inhibiting the reabsorption, or reuptake, of two vital neurotransmitters: Serotonin and Norepinephrine. The resulting increase in the concentration of these messengers underpins its ability to stabilize mood regulation. This dual action on monoaminergic neurotransmission provides the chemical basis for Levate's general purpose in restoring equilibrium.

Regulatory References

  1. Amitriptyline - StatPearls - NCBI Bookshelf - NIH
  2. Amitriptyline - LiverTox - NCBI Bookshelf - NIH

What side effects are possible with Levate?

Possible Side Effects and Safety Information

The safety profile of Levate (Amitriptyline) is established by regulatory documentation, which classifies potential reactions by observed frequency and the physiological system affected. This section details adverse reactions and safety constraints strictly as documented in official government labeling.


Regulatory Classification of Adverse Reactions

Adverse reactions are classified into frequency categories based on regulatory standards. Reactions designated as Very Common (may affect more than 1 in 10 people) typically include dry mouth, somnolence (drowsiness), dizziness, and headache. Common reactions (may affect up to 1 in 10 people) involve systems such as the cardiovascular (e.g., orthostatic hypotension, tachycardia) and metabolic (e.g., weight gain), alongside constipation and confusion. Rare but documented effects include jaundice, certain blood disorders, and bone marrow depression.


Serious Safety Considerations and Constraints

Official labeling carries a Boxed Warning detailing an increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24), a risk noted to be highest early during treatment and upon dose changes. Serious safety risks also include potential cardiac arrhythmias, QT interval prolongation, and the possibility of Serotonin Syndrome when used with certain other medications. Levate is formally contraindicated during the acute recovery phase following a heart attack and for individuals with severe hepatic impairment. Older adults are officially noted as having increased susceptibility to anticholinergic effects and orthostatic hypotension, requiring careful consideration based on the official safety documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the clinical manifestations of overdose and the required emergency actions as strictly documented in official government regulatory sources.

Category Documented Manifestations and Actions
Documented Manifestations Clinical signs include severe CNS depression (drowsiness, stupor, confusion, leading to coma), neurological signs such as seizures and hallucinations, and profound anticholinergic effects (e.g., mydriasis, urinary retention).
Cardiovascular Outcomes Overdose can result in life-threatening cardiotoxicity, including cardiac dysrhythmias, severe hypotension, and QRS-complex widening on an ECG, with a QRS interval exceeding 0.16 seconds indicating severe toxicity.
Required Emergency Action Suspected overdose requires an individual to seek emergency medical attention or call the Poison Help line immediately. Due to the high risk of fatality, patients are almost always admitted to the hospital for observation.
Supportive Care & Monitoring Treatment is officially described as symptomatic and supportive. No specific antidote is known. Required procedures include continuous ECG monitoring, potentially for several days, and the use of activated charcoal or gastric lavage under appropriate conditions.
Population Note The official labeling notes that children are especially susceptible to severe outcomes, including specific symptoms like hyponatremia. Elderly patients are also at higher risk for severe toxicity.

Connection to the overall overdose profile: Regulatory documents define the Levate overdose profile primarily by its potential for rapid, severe toxicity involving critical cardiovascular and CNS effects. The need for urgent medical care is explicitly mandated by the risk of circulatory failure and seizures. Management focuses on symptomatic and supportive treatment, given the lack of a specific antidote, and requires mandatory hospital observation.

Therapeutic Uses of Levate

What Levate Treats: Main Uses and Benefits

Levate offers supportive relief across key therapeutic domains, addressing symptomatic manifestations that may create noticeable physiological strain or distress. It is commonly used to help patients cope more steadily with difficult or chronic episodes and supports maintaining a sense of stability when symptoms are more noticeable. This medication is applied across several clinical areas to ease symptom burden.

The medicine is relevant for conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), certain neuropathic pain syndromes (like postherpetic neuralgia and diabetic neuropathy), and for the prophylactic management of recurrent migraines. It is also relevant for easing symptoms linked to organ-specific functional stress, such as Irritable Bowel Syndrome (IBS) and persistent nocturnal enuresis in the appropriate pediatric population.


Quick Fact: Relief for Chronic Discomfort

Symptom Domain Key Use Context Primary Benefit
Profoundly Lowered Mood Managing Major Depressive symptoms. Contributes to general well-being.
Neuropathic Pain Long-standing burning, shooting pain. Contributes to easing discomfort.
Recurrent Headaches Prophylactic management of migraines. Assists with symptomatic management.

Regulatory References

  1. NIH StatPearls clinical overview of Amitriptyline

Eligibility and Restrictions for Use

Who Can and Cannot Use Levate?

This section outlines the official population eligibility and non-eligibility rules for Levate (Amitriptyline Hydrochloride) as mandated by regulatory bodies like the FDA and EMA.


Contraindicated Populations

Levate is contraindicated (must not be used) for several populations, including patients with known hypersensitivity to Amitriptyline and those who have recently had a myocardial infarction (heart attack). It is also prohibited for patients with certain cardiac issues, such as heart block or disorders of cardiac rhythm, and for individuals with severe liver disease.

Use is strictly prohibited for patients taking Monoamine Oxidase Inhibitors (MAOIs), requiring a 14-day gap when switching between treatments.


Age and Comorbidity Restrictions

Population Group Regulatory Status
Children under 6 years Contraindicated for all uses.
Children 6+ to Adolescents (under 18) Not recommended for depression or pain; approved only for nocturnal enuresis.
Older Adults (Geriatric) Use requires caution and close monitoring due to increased susceptibility to effects.
Pregnancy/Lactation Not recommended unless clearly necessary; use during breastfeeding is conditional.

For adults with certain pre-existing conditions, such as a history of seizures, angle-closure glaucoma, or urinary retention, Levate must be used with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify Levate (Amitriptyline HCl) interactions based on pharmacodynamic and pharmacokinetic mechanisms, establishing mandatory restrictions.


Official Interaction Restrictions and Risks

Interaction Type Regulatory Restriction/Outcome
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. Must not be co-administered due to risk of severe Serotonin Syndrome and hyperpyretic crisis. A minimum 14-day separation period is required when switching therapies.
Pharmacokinetic Inhibition Strong CYP2D6 inhibitors (e.g., Bupropion, Paroxetine) are documented to increase Levate's plasma concentration by inhibiting its metabolism.
Serotonergic Agents Concomitant use with other serotonergic drugs (e.g., SSRIs, Tramadol, St. John's Wort) increases the official, documented risk of Serotonin Syndrome.
CNS Depressants & Alcohol Co-administration with other CNS depressants (e.g., Opioids) or alcohol can produce additive sedation and enhanced effects.

These interactions are formally documented in official prescribing information. Levate may also block the blood pressure-lowering action of Guanethidine and similar antihypertensive compounds. Additionally, Elderly Patients and those identified as CYP2D6 Poor Metabolizers are noted in regulatory documents as having reduced clearance, which may lead to higher than expected plasma concentrations.

Mechanism of Action

Modulation of Presynaptic Signal Release

This domain centers on Levate's high-affinity binding to the Synaptic Vesicle Protein 2A (SV2A), a protein essential for the release of chemical messengers (neurotransmitters) between nerve cells. This action modifies early molecular steps in the signaling sequence, which reduces the probability of excessive or abnormal signal transmission and results in altered neuronal signal flow.


Influence on Neuronal Firing Dynamics

This mechanistic domain reflects how Levate's actions, including its influence on certain ion channels (like calcium channels), collectively modulate the probability for nerve cells to fire in rapid, synchronized bursts. It primarily affects systems where electrical signaling dominates, influencing the control mechanisms of processes driven by distinct, high-frequency firing patterns. This process produces a shift in pathway dynamics, which defines the resultant physiological changes.


Adjustment of Central Neural Communication

Levate engages mechanisms that influence the dynamics of signaling primarily within the central nervous system. By targeting the fundamental machinery responsible for neurotransmitter release, the drug alters the ratio of signal transmission and controlled flow of information across key neural circuits. This decreases the intensity of excessive mediator activity and modulates the flow of high-frequency signal propagation in the brain.

Dosage and Administration Information

How to Use Levate

Levate (Amitriptyline Hydrochloride) is an oral tablet intended to be swallowed whole with water, and may be taken either with or without food.


Official Dosing Patterns

Standard dosing for adults typically begins with a low initial dose to allow the body to adjust. For outpatient management, the starting daily dose often ranges between 50 mg to 75 mg which can be taken once daily or in divided doses. The total daily quantity is most commonly consolidated and administered as a single dose at bedtime (qHS) due to its pronounced sedative characteristics, promoting consistency in the daily schedule.

Administration Principle Standard Requirement
Administration Route Oral (tablet form)
Dosing Frequency Typically Once Daily (at bedtime)
Adult Maintenance Range 40 mg to 100 mg per day
Maximum Outpatient Dose 150 mg per day

Dosage Adjustment and Duration

Treatment involves a gradual titration process, where the starting dose is increased slowly over several days or weeks to establish the most appropriate therapeutic level. Levate must never be stopped abruptly; instead, the dose must be slowly tapered (gradually reduced) over a period of weeks to minimize the potential for withdrawal-like symptoms. For long-term use, the maintenance phase for certain indications may extend for many months or longer following the initial period of improvement.

Population-Specific Guidelines

Specific populations require dose adjustments. Older adults typically begin at a significantly lower initial dose, such as 10 mg to 25 mg daily, and generally should not exceed 100 mg per day. Patients with confirmed hepatic impairment may also require a reduction (up to 50%) of the usual starting dose. If a dose is missed, the standard approach is to skip that dose and return to the regular schedule; doubling a dose is not permitted.

Recent Clinical Evidence

Research evidence / Overview of studies for Levate (Amitriptyline HCl)

This section provides a descriptive overview of the clinical evaluation of Levate, summarizing the formal research evidence, including randomized controlled trials (RCTs) and systematic reviews, as described in authoritative governmental and peer-reviewed scientific sources. The overview describes what outcomes were measured and the populations studied, without offering clinical guidance, recommendations, or interpretations of individual results.


Evidence for Use in Major Depressive Disorder (MDD)

Levate was studied for use in Major Depressive Disorder (MDD) in adult populations. The evidence base consists of numerous short-term Randomized Controlled Trials (RCTs) and Systematic Reviews.

Researchers monitored outcomes related to episodic or acute changes in mood by measuring standardized depressive symptom scores. The certainty of this evidence for acute changes compared to placebo is generally categorized as High. However, long-term effects are not fully established beyond the acute phase, and there is limited information for long-term outcomes regarding the sustained pattern of changes observed.


Evidence for Use in Chronic Neuropathic Pain

Levate was evaluated in research examining patterns related to persistent neuropathic pain syndromes, such as Post-Herpetic Neuralgia (PHN) and Diabetic Neuropathic Pain (PDN). Studies focused on changes in pain intensity reported by patients and outcomes related to sleep quality or disruption in adults.

Studies report patterns related to short-term changes in pain scores, and the evidence level for the short-term outcomes measured is broadly categorized as High. Nevertheless, follow-up durations were limited in many core trials, and evidence quality varies across studies, leading to uncertainty regarding the overall clinical significance of observed short-term changes.


Evidence Gaps and Areas of Scientific Uncertainty

Long-term effects are not fully established across most indications, particularly regarding sustained outcomes and functional balance. For some historical conditions, the body of evidence relies heavily on older trials where sample sizes were modest and evidence quality varies across studies, which can limit the certainty of findings. Comparative evidence is lacking for Levate against many of the newer available options. Research provides context but does not determine whether an individual will respond similarly; findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Levate (FAQ)


Q: Is Levate a controlled substance?

Levate (Amitriptyline) is a prescription-only medicine, meaning you need a prescription from a healthcare provider to obtain it. However, according to official regulatory classification from agencies like the FDA, it is not classified as a federally controlled substance.


Q: Is it common to feel a bit tired when starting Levate?

Official regulatory documents list somnolence (drowsiness) and tiredness as Very Common side effects, meaning they may affect more than 1 in 10 people. These effects are often most noticeable during the initial phase of treatment or when the dosage is changed. Regulatory labeling indicates that the medication is frequently administered as a single daily dose, often at bedtime, which is a common prescribing pattern.


Q: Can Levate be taken while using common supplements like vitamins or herbal remedies?

Official information warns against combining Levate with certain herbal remedies, such as St. John's Wort, due to a documented risk of Serotonin Syndrome. Official documents describe the importance of full disclosure to the healthcare provider regarding all concurrent products, including vitamins and herbal remedies, because some supplements are documented to have potential interactions that may affect the drug's activity.


Q: Can I drive or operate machinery after taking Levate?

Because Levate can cause side effects like dizziness, drowsiness, and blurred vision, regulatory labeling indicates caution. If an individual experiences these effects, they must avoid activities like driving, operating machinery, or any other potentially dangerous activity until they know how the medication affects them.


Q: Are there any specific foods or drinks that should be avoided with Levate?

The use of alcohol is advised against because it can produce additive sedation and enhanced effects like dizziness. Furthermore, some authoritative sources indicate that consuming grapefruit or grapefruit juice may potentially affect how the drug is metabolized in the body, which could increase its concentration.


Q: Can Levate be used during pregnancy or while breastfeeding?

Use during pregnancy is generally not recommended unless considered clearly necessary. Regarding breastfeeding, the active substance is found in low levels in breast milk. Regulatory information advises caution for breastfeeding infants, especially for those under two months old, due to the potential for effects such as sedation.


Q: Does Levate interact with grapefruit?

Yes, grapefruit, including grapefruit juice, may interact with Levate. This is because certain components of grapefruit can affect the enzyme system responsible for breaking down the drug, which may lead to higher concentrations of Levate in the body.


Q: Is Levate safe for long-term use?

The required duration of treatment varies depending on the medical condition. Regulatory sources state that for certain chronic conditions, therapy may be required for periods of months or years. Regulatory documents indicate that regular medical reassessment is part of the standard protocol for continued treatment to confirm the ongoing appropriateness of the therapy.


Q: Does Levate cause any mood changes or anxiety?

Official labeling contains a Boxed Warning that advises monitoring for new or worsening symptoms of anxiety, agitation, or irritability, particularly early in treatment. Additionally, Levate may rarely induce mania in individuals with certain risk factors, such as a history of bipolar disorder.


Q: Can Levate affect the results of certain lab tests?

Regulatory documents note that Levate can cause changes in blood or urine sugar levels and may affect results of certain laboratory tests. The labeling notes the importance of informing the doctor or lab technician that the medication is being taken before undergoing any tests.


Q: Is 'brain fog' or cognitive impairment a documented side effect of Levate (Amitriptyline)?

The official safety information describes anticholinergic side effects that include confusion and delirium, which may be experienced by users as 'brain fog' or cognitive impairment. Regulatory documents specifically note that older adults are more susceptible to these effects.


Q: Can Levate be taken with birth control pills?

Authoritative medical resources indicate that Levate is not listed among medications known to significantly reduce the effectiveness of hormonal contraceptives, including the combined birth control pill.


Q: Is there any information about Levate use in people with kidney or liver conditions?

Levate is contraindicated (must not be used) for individuals with severe liver disease. For patients with reduced liver function, careful dose adjustment may be necessary. Reduced kidney function typically has no significant influence on how the drug is processed, and standard doses are often given.


Q: Can Levate affect vision?

Yes, blurred vision is a commonly reported side effect. Additionally, Levate must be used with caution in patients with a history of angle-closure glaucoma, as official documents note that it can potentially worsen this condition.


Q: What is the half-life of Levate?

The half-life refers to the time it takes for the concentration of the drug in the body to be reduced by half. Regulatory and authoritative sources typically report the half-life of Levate (Amitriptyline) as ranging between 12 and 36 hours.


Q: Which medical specialties are commonly associated with prescribing Amitriptyline?

Based on its officially approved uses, Levate is commonly prescribed by specialists in several fields. These include psychiatry (for mood disorders), neurology or pain management (for neuropathic pain and related uses), and general internal medicine/primary care.

How should Levate be stored and disposed of?

How to Store and Dispose of Levate?

Levate (Amitriptyline Hydrochloride) tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light, excess heat, and moisture.


Storage Requirements

  • Store the tablets in the original container and ensure it remains tightly closed.
  • The medication must be stored out of the sight and reach of children and secured with a locked safety cap.

Disposal Instructions

Unused or expired Levate should not be flushed down a toilet or poured down a sink. Instead, if a medicine take-back program is unavailable, mix the tablets with an undesirable substance (such as dirt or used coffee grounds), seal the mixture in a bag, and discard it in the household trash. Identifying information must be removed from the prescription label prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levate found in:

A-Z Index: